TBX 3400

Drug Profile

TBX 3400

Alternative Names: TBX-3400

Latest Information Update: 08 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taiga Biotechnologies
  • Class Antineoplastics; Cell therapies; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Infections; Malignant melanoma; Solid tumours

Most Recent Events

  • 08 Jan 2018 Preclinical trials in Solid tumours and Infections in USA (IV) before January 2018
  • 28 Dec 2017 Preclinical trials in Malignant melanoma in USA (IV) before December 2017 (NCT03385486)
  • 28 Dec 2017 Taiga Biotechnologies plans a phase I trial for Malignant melanoma (Late-stage disease, Refractory metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (NCT03385486)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top